Literature DB >> 19926288

Nervous yeast: modeling neurotoxic cell death.

Ralf J Braun1, Sabrina Büttner, Julia Ring, Guido Kroemer, Frank Madeo.   

Abstract

Neurodegeneration is characterized by the disease-specific loss of neuronal activity, culminating in the irreversible destruction of neurons. Neuronal cell death can proceed via distinct subroutines such as apoptosis and necrosis, but the underlying molecular mechanisms remain poorly understood. Saccharomyces cerevisiae is an established model for programmed cell death, characterized by distinct cell death pathways conserved from yeast to mammals. Recently, yeast models for several major classes of neurodegeneration, namely alpha-synucleinopathies, polyglutamine disorders, beta-amyloid diseases, tauopathies, and TDP-43 proteinopathies, have been established. Heterologous expression of the human proteins implicated in these disorders has unraveled important insights in their detrimental function, pointing to ways in which yeast might advance the mechanistic dissection of cell death pathways relevant for human neurodegeneration. Copyright 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19926288     DOI: 10.1016/j.tibs.2009.10.005

Source DB:  PubMed          Journal:  Trends Biochem Sci        ISSN: 0968-0004            Impact factor:   13.807


  35 in total

1.  The yeast product Milmed enhances the effect of physical exercise on motor performance and dopamine neurochemistry recovery in MPTP-lesioned mice.

Authors:  Trevor Archer; Anders Fredriksson
Journal:  Neurotox Res       Date:  2013-07-27       Impact factor: 3.911

2.  Identification of PrP sequences essential for the interaction between the PrP polymers and Aβ peptide in a yeast-based assay.

Authors:  Aleksandr A Rubel; Tatyana A Ryzhova; Kirill S Antonets; Yury O Chernoff; Alexey Galkin
Journal:  Prion       Date:  2013-10-23       Impact factor: 3.931

3.  High-throughput analysis of yeast replicative aging using a microfluidic system.

Authors:  Myeong Chan Jo; Wei Liu; Liang Gu; Weiwei Dang; Lidong Qin
Journal:  Proc Natl Acad Sci U S A       Date:  2015-07-13       Impact factor: 11.205

Review 4.  Probing the role of structural features of mouse PrP in yeast by expression as Sup35-PrP fusions.

Authors:  Lyne Jossé; Ricardo Marchante; Jo Zenthon; Tobias von der Haar; Mick F Tuite
Journal:  Prion       Date:  2012-07-01       Impact factor: 3.931

Review 5.  Yeast prions: structure, biology, and prion-handling systems.

Authors:  Reed B Wickner; Frank P Shewmaker; David A Bateman; Herman K Edskes; Anton Gorkovskiy; Yaron Dayani; Evgeny E Bezsonov
Journal:  Microbiol Mol Biol Rev       Date:  2015-03       Impact factor: 11.056

Review 6.  Modeling ALS and FTLD proteinopathies in yeast: an efficient approach for studying protein aggregation and toxicity.

Authors:  Dmitry Kryndushkin; Frank Shewmaker
Journal:  Prion       Date:  2011-10-01       Impact factor: 3.931

Review 7.  How to bake a brain: yeast as a model neuron.

Authors:  Isabella Sarto-Jackson; Lubomir Tomaska
Journal:  Curr Genet       Date:  2016-01-18       Impact factor: 3.886

8.  PABPN1 suppresses TDP-43 toxicity in ALS disease models.

Authors:  Ching-Chieh Chou; Olga M Alexeeva; Shizuka Yamada; Amy Pribadi; Yi Zhang; Bi Mo; Kathryn R Williams; Daniela C Zarnescu; Wilfried Rossoll
Journal:  Hum Mol Genet       Date:  2015-06-30       Impact factor: 6.150

9.  Evaluation of the Impact of Protein Aggregation on Cellular Oxidative Stress in Yeast.

Authors:  Anita Carija; Salvador Ventura; Susanna Navarro
Journal:  J Vis Exp       Date:  2018-06-23       Impact factor: 1.355

10.  Latrepirdine (dimebon) enhances autophagy and reduces intracellular GFP-Aβ42 levels in yeast.

Authors:  Prashant R Bharadwaj; Giuseppe Verdile; Renae K Barr; Veer Gupta; John W Steele; M Lenard Lachenmayer; Zhenyu Yue; Michelle E Ehrlich; Gregory Petsko; Shulin Ju; Dagmar Ringe; Sonia E Sankovich; Joanne M Caine; Ian G Macreadie; Sam Gandy; Ralph N Martins
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.